Literature DB >> 32524020

SEVERE INSULIN RESISTANCE WITH DIABETIC KETOACIDOSIS AFTER BRENTUXIMAB TREATMENT.

Janet M Chiang, Andrew R Lai, Mark Anderson, Robert J Rushakoff.   

Abstract

OBJECTIVE: To increase awareness of unusual inflammatory and other responses including severe insulin resistance (IR) associated with the use of targeted immunotherapies such as brentuximab.
METHODS: We report the case of a man without any previous diagnosis of diabetes who developed diabetic ketoacidosis complicated by severe IR (unresponsive to >600 units of intravenous insulin per hour) after receiving brentuximab for Hodgkin lymphoma.
RESULTS: Autoantibodies to the insulin receptor were not detected in the patient's serum, thus excluding a diagnosis of type B IR.
CONCLUSION: We hypothesize that brentuximab administration led to a rare reaction leading to systemic cytokine release with extreme IR in our patient.
Copyright © 2020 AACE.

Entities:  

Year:  2020        PMID: 32524020      PMCID: PMC7282153          DOI: 10.4158/ACCR-2019-0435

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  11 in total

1.  Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.

Authors:  C Kurts; F R Carbone; M F Krummel; K M Koch; J F Miller; W R Heath
Journal:  Nature       Date:  1999-03-25       Impact factor: 49.962

2.  Brentuximab associated progressive multifocal leukoencephalopathy.

Authors:  Pankaj Jalan; Aman Mahajan; Vijay Pandav; Simon Bekker; Janak Koirala
Journal:  Clin Neurol Neurosurg       Date:  2012-04-01       Impact factor: 1.876

3.  Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.

Authors:  Nina D Wagner-Johnston; Nancy L Bartlett; Amanda Cashen; Joseph R Berger
Journal:  Leuk Lymphoma       Date:  2012-04-23

4.  Successful treatment of Type B insulin resistance in a patient with otherwise quiescent systemic lupus erythematosus.

Authors:  A P Coll; D Morganstein; D Jayne; M A Soos; S O'Rahilly; J Burke
Journal:  Diabet Med       Date:  2005-06       Impact factor: 4.359

5.  Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.

Authors:  Robert Zeiser; Vu H Nguyen; Jing-Zhou Hou; Andreas Beilhack; Elizabeth Zambricki; Martin Buess; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

6.  Extensive toxic epidermal necrolysis following brentuximab vedotin administration.

Authors:  Maria Ilaria Del Principe; Giuseppe Sconocchia; Francesco Buccisano; Mariagiovanna Cefalo; Ambra Di Veroli; Giovanna De Santis; Daniela Nasso; Luca Maurillo; Lucia Anemona; Massimiliano Postorino; Giovanni Del Poeta; Sergio Amadori; Adriano Venditti
Journal:  Ann Hematol       Date:  2014-07-02       Impact factor: 3.673

Review 7.  Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.

Authors:  Stefan K Alig; Martin Dreyling; Bettina Seppi; Benedikt Aulinger; Lukas Witkowski; Christina T Rieger
Journal:  Eur J Haematol       Date:  2014-07-02       Impact factor: 2.997

8.  CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role.

Authors:  R Gerli; C Pitzalis; O Bistoni; B Falini; V Costantini; A Russano; C Lunardi
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

9.  Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Authors:  Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

10.  Type B Insulin Resistance Masquerading as Ovarian Hyperthecosis.

Authors:  Rebecca J Brown; Jalaja Joseph; Elaine Cochran; Cornelia Gewert; Robert Semple; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2017-06-01       Impact factor: 5.958

View more
  1 in total

1.  Brentuximab vedotin-associated diabetic ketoacidosis: a case report.

Authors:  Damla Köksalan; Mehmet Sözen; Alev Selek; Emre Gezer; Zeynep Cantürk; Berrin Çetinarslan
Journal:  Int J Diabetes Dev Ctries       Date:  2022-07-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.